Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Exenatide.

Anthony H Barnett1

  • 1University of Birmingham and Birmingham Heartlands and Solihull National Health Service Trust Teaching, UK. anthony.barnett@ heartofengland.nhs.uk

Drugs of Today (Barcelona, Spain : 1998)
|December 13, 2005
PubMed
Summary

Exenatide, a glucagon-like peptide-1 (GLP-1) receptor agonist, improves glycemic control in type 2 diabetes by enhancing insulin secretion and reducing glucagon levels. This therapy offers potential for reduced hypoglycemia and weight gain, representing significant therapeutic advancements.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ultra-long-acting insulin: a new chapter in diabetes therapy?

The lancet. Diabetes & endocrinology·2024
Same author

Insulin icodec: evolution or revolution in diabetes therapy?

The lancet. Diabetes & endocrinology·2023
Same author

SGLT2 inhibitors in older adults: overcoming the age barrier.

The lancet. Healthy longevity·2023
Same author

Improving management of diabetic kidney disease: will GLP-1 receptor agonists have a role?

The lancet. Diabetes & endocrinology·2020
Same author

Glucokinase Activators for Type 2 Diabetes: Challenges and Future Developments.

Drugs·2020
Same author

Evidence-based prescribing of diabetes medications: are we getting closer?

The lancet. Diabetes & endocrinology·2020

Area of Science:

  • Pharmacology
  • Endocrinology
  • Metabolic Diseases

Background:

  • Glucagon-like peptide-1 (GLP-1) is a naturally occurring hormone regulating glucose homeostasis.
  • GLP-1 stimulates insulin release and suppresses glucagon secretion in response to food intake.
  • Exenatide is a novel agent mimicking GLP-1 actions for diabetes management.

Purpose of the Study:

  • To evaluate the efficacy and safety of exenatide in improving glycemic control.
  • To assess exenatide's impact on key diabetes-related parameters including HbA1c and body weight.
  • To understand the mechanisms by which exenatide improves glucose regulation.

Main Methods:

  • Exenatide's effects were studied based on its pharmacological actions.
  • Mechanisms include glucose-dependent insulin stimulation, glucagon suppression, and slowed gastric emptying.
  • Clinical outcomes such as HbA1c reduction and weight changes were assessed.

Main Results:

  • Exenatide demonstrated glucose-dependent insulin secretion and glucagon suppression.
  • Significant, dose-dependent reductions in HbA1c and body weight were observed.
  • Nausea was the most common side effect, manageable with dose titration.

Conclusions:

  • Exenatide effectively improves glycemic control in type 2 diabetes.
  • The drug offers benefits of reduced hypoglycemia risk and weight loss.
  • Exenatide represents a significant therapeutic option for managing type 2 diabetes.

Related Experiment Videos